Reliability and Validity of Transcranial Magnetic Stimulation-Electroencephalography Biomarkers.

Electroencephalography (EEG) Reliability TMS-EEG Transcranial magnetic stimulation (TMS) Transcranial magnetic stimulation–evoked potentials (TEP) Validity

Journal

Biological psychiatry. Cognitive neuroscience and neuroimaging
ISSN: 2451-9030
Titre abrégé: Biol Psychiatry Cogn Neurosci Neuroimaging
Pays: United States
ID NLM: 101671285

Informations de publication

Date de publication:
08 2023
Historique:
received: 15 07 2022
revised: 15 11 2022
accepted: 11 12 2022
pmc-release: 01 08 2024
medline: 8 8 2023
pubmed: 10 3 2023
entrez: 9 3 2023
Statut: ppublish

Résumé

Noninvasive brain stimulation and neuroimaging have revolutionized human neuroscience with a multitude of applications, including diagnostic subtyping, treatment optimization, and relapse prediction. It is therefore particularly relevant to identify robust and clinically valuable brain biomarkers linking symptoms to their underlying neural mechanisms. Brain biomarkers must be reproducible (i.e., have internal reliability) across similar experiments within a laboratory and be generalizable (i.e., have external reliability) across experimental setups, laboratories, brain regions, and disease states. However, reliability (internal and external) is not alone sufficient; biomarkers also must have validity. Validity describes closeness to a true measure of the underlying neural signal or disease state. We propose that these metrics, reliability and validity, should be evaluated and optimized before any biomarker is used to inform treatment decisions. Here, we discuss these metrics with respect to causal brain connectivity biomarkers from coupling transcranial magnetic stimulation (TMS) with electroencephalography (EEG). We discuss controversies around TMS-EEG stemming from the multiple large off-target components (noise) and relatively weak genuine brain responses (signal), as is unfortunately often the case in noninvasive human neuroscience. We review the current state of TMS-EEG recordings, which consist of a mix of reliable noise and unreliable signal. We describe methods for evaluating TMS-EEG biomarkers, including how to assess internal and external reliability across facilities, cognitive states, brain networks, and disorders and how to validate these biomarkers using invasive neural recordings or treatment response. We provide recommendations to increase reliability and validity, discuss lessons learned, and suggest future directions for the field.

Identifiants

pubmed: 36894435
pii: S2451-9022(22)00340-8
doi: 10.1016/j.bpsc.2022.12.005
pmc: PMC10276171
mid: NIHMS1859299
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

805-814

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH126639
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH129018
Pays : United States

Informations de copyright

Published by Elsevier Inc.

Auteurs

Sara Parmigiani (S)

Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, California; Veterans Affairs Palo Alto Healthcare System, and the Sierra Pacific Mental Illness, Research, Education, and Clinical Center, Palo Alto, California; Wu Tsai Neuroscience Institute, Stanford, California.

Jessica M Ross (JM)

Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, California; Veterans Affairs Palo Alto Healthcare System, and the Sierra Pacific Mental Illness, Research, Education, and Clinical Center, Palo Alto, California; Wu Tsai Neuroscience Institute, Stanford, California.

Christopher C Cline (CC)

Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, California; Veterans Affairs Palo Alto Healthcare System, and the Sierra Pacific Mental Illness, Research, Education, and Clinical Center, Palo Alto, California; Wu Tsai Neuroscience Institute, Stanford, California.

Christopher B Minasi (CB)

Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, California; Veterans Affairs Palo Alto Healthcare System, and the Sierra Pacific Mental Illness, Research, Education, and Clinical Center, Palo Alto, California; Wu Tsai Neuroscience Institute, Stanford, California.

Juha Gogulski (J)

Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, California; Veterans Affairs Palo Alto Healthcare System, and the Sierra Pacific Mental Illness, Research, Education, and Clinical Center, Palo Alto, California; Wu Tsai Neuroscience Institute, Stanford, California; Department of Clinical Neurophysiology, HUS Diagnostic Center, Clinical Neurosciences, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Corey J Keller (CJ)

Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, California; Veterans Affairs Palo Alto Healthcare System, and the Sierra Pacific Mental Illness, Research, Education, and Clinical Center, Palo Alto, California; Wu Tsai Neuroscience Institute, Stanford, California. Electronic address: ckeller1@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH